Other substances

(Recombinant) IL-2

A cytokine.

Phase of research

Potential treatment - clinical evidence

How it helps

Other treatment

Drug status

Experimental

Supporting references

Contradictory references

AI-suggested references

Clinical trials

General information

(Recombinant) IL-2 is a cytokine, which acts on multiple receptors. IL-2 stimulates cytotoxic effector T cells and also regulatory T cells. It manifests both immunostimulatory (high doses) and immunosuppressive (low doses) properties (Arenas-Ramirez et al., 2015).

(Recombinant) IL-2 on DrugBank
(Recombinant) IL-2 on Wikipedia
(Recombinant) IL-2 structure on PDB

Synonyms

rIL-2; (Recombinant) human interleukin 2; interleukin-2

MYRMQLLSCIALSLALVTNSAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLNRWITFCQSIISTLT (precursor)

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
Recombinant interleukin-2 stimulates lymphocyte recovery in patients with severe COVID-19 Severe severity Protein factor Cohort study	Severe COVID-19 patients	1.79	Compared to control, upon rIL-2 administration there was a statistically significantly higher increase in lymphocyte count. Improvement in inflammatory parameters was observed, as well, but it was not significant compared to control. Sample size: 20 + 39 control (20 matched control). Dosage: Subcutaneously 1x10^6 IU daily for 7-10 days.	Jan/18/2021

AI-suggested references

Link	Publication date
Delayed-interval BNT162b2 mRNA COVID-19 vaccination enhances humoral immunity and induces robust T cell responses.	Feb/03/2022
SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study	Mar/23/2022
Durable T-cellular and humoral responses in SARS-CoV-2 hospitalized and community patients	Aug/30/2020
Data on immunogenicity and reactogenicity to COVID-19 vaccination among patients receiving maintenance dialysis.	May/16/2022
Evaluating the Response and Safety of Inactivated COVID-19 Vaccines in Liver Transplant Recipients	May/12/2022
Efficacy of ACEIs/ARBs vs CCBs on the progression of COVID-19 patients with hypertension in Wuhan: A hospital-based retrospective cohort study.	Oct/05/2020
Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2	Mar/14/2022
Multisystem Inflammatory Syndrome in an Adult With COVID-19-A Trial of Anakinra: A Case Report.	May/15/2021
Rituximab Impairs B Cell Response But Not T Cell Response to COVID-19 Vaccine in Autoimmune Diseases	Mar/29/2022
Immunogenicity and reactogenicity of homologous mRNA-based and vector-based SARS-CoV-2 vaccine regimens in patients receiving maintenance dialysis	Feb/25/2022
Examining the effector mechanisms of Xuebijing injection on COVID-19 based on network pharmacology.	Oct/16/2020
Safety, immunogenicity, and protection provided by unadjuvanted and adjuvanted formulations of a recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in nonhuman primates	Jan/05/2022
Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine	May/30/2021
TRIM28 regulates SARS-CoV-2 cell entry by targeting ACE2	Jun/17/2021
Ibrutinib for chronic lymphocytic leukemia in the setting of respiratory failure from severe COVID-19 infection: Case report and literature review.	Sep/20/2020

Export (.csv)